Reaction
Noninfective Gingivitis reporting signals
As of the last recalculation, Noninfective Gingivitis appears in 1,422 FAERS reports alongside 25 co-occurring drug terms. The strongest observed disproportionality signal is CETIIRIZINE (PRR 22.7).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Cetiirizine | 63 | 22.7 | 22.8 |
| Tofacitinib Citrate | 17 | 19.2 | 19.2 |
| Antacid | 57 | 18.3 | 18.3 |
| Cetirizine | 79 | 15.7 | 15.7 |
| Calcium Carbonate | 57 | 12.9 | 12.9 |
| Ramipril | 93 | 11.7 | 11.7 |
| Clopidogrel Bisulfate | 77 | 11.6 | 11.6 |
| Mirtazapine | 62 | 10.3 | 10.3 |
| Oxybutynin Chloride | 6 | 10.1 | 10.1 |
| Everolimus | 34 | 10.0 | 10.0 |
| Buprenorphine Hydrochloride, Naloxone Hydrochloride | 15 | 9.2 | 9.2 |
| Cabozantinib | 29 | 9.0 | 9.0 |
| Sotalol Hydrochloride | 10 | 8.9 | 8.9 |
| Alpelisib | 5 | 8.4 | 8.4 |
| Sunitinib Malate | 21 | 7.9 | 7.9 |
| Ocrelizumab | 29 | 7.0 | 7.0 |
| Denosumab | 89 | 6.8 | 6.8 |
| Cannabidiol | 9 | 5.7 | 5.7 |
| Pazopanib Hydrochloride | 10 | 5.4 | 5.4 |
| Romosozumab-Aqqg | 5 | 5.4 | 5.4 |
| Axitinib | 7 | 5.3 | 5.3 |
| Palbociclib | 32 | 5.0 | 5.0 |
| Ofatumumab | 10 | 4.4 | 4.4 |
| Abaloparatide | 5 | 2.5 | 2.5 |
| Nirmatrelvir And Ritonavir | 7 | 1.9 | 1.9 |